U.S. markets open in 1 hour 32 minutes

American Renal Associates Holdings, Inc. (ARA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
6.25-0.01 (-0.16%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close6.26
Open6.27
Bid0.00 x 3000
Ask6.44 x 800
Day's Range6.23 - 6.34
52 Week Range5.57 - 10.60
Volume35,238
Avg. Volume65,147
Market Cap216.298M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • American Renal Associates Holdings, Inc. Announces Settlement of Shareholder Derivative Litigation
    Business Wire

    American Renal Associates Holdings, Inc. Announces Settlement of Shareholder Derivative Litigation

    American Renal Associates Holdings, Inc. (NYSE: ARA) (the "Company"), a leading provider of outpatient dialysis services, is pleased to announce that the Company has received preliminary approval of the settlement of a stockholder derivative action brought by Plaintiff Luke Johnson, and pending in the United States District Court for the District of New Jersey (case number No. 19-cv-15812) (the "Johnson Action"). The proposed settlement releases all claims asserted against the Company and the other named defendants in the Johnson Action without any liability or wrongdoing attributed to them. The proposed settlement remains subject to court approval and other customary conditions.

  • How Has American Renal Associates Holdings (NYSE:ARA) Allocated Its Capital?
    Simply Wall St.

    How Has American Renal Associates Holdings (NYSE:ARA) Allocated Its Capital?

    When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...

  • American Renal Associates Holdings, Inc. Announces Second Quarter 2020 Results
    Business Wire

    American Renal Associates Holdings, Inc. Announces Second Quarter 2020 Results

    American Renal Associates Holdings, Inc. (NYSE: ARA) (the "Company"), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the second quarter ended June 30, 2020. The Company also provided an update on its COVID-19 impact and affirmed its 2020 Adjusted EBITDA less noncontrolling interests ("Adjusted EBITDA-NCI") Outlook. These updates are highlighted later in this release.